We are thrilled to announce that Thomas G. O’Riordan, MD, MPH, Vice President US Medical and Therapy Head for Respiratory at GlaxoSmithKline (GSK), will assume the role of Editor-in-Chief of Journal of Aerosol Medicine and Pulmonary Drug Delivery, published by Mary Ann Liebert, Inc.
“I am honored to be selected as Editor-in-Chief with the opportunity to build on the great work of the founding Editor-in-Chief, Dr. Gerry Smaldone and the Associate Editor, Dr. Tim Corcoran. I look forward to working with the publisher, editorial board, and with many reviewers who generously devote their time to ensuring that the Journal publishes impactful high-quality research and to continuing close collaboration with the International Society for Aerosols in Medicine.”
Dr. O’Riordan is currently Vice President US Medical and Therapy Head for Respiratory at GSK, having worked previously at Sanofi and Gilead. Tom graduated from University College Dublin with an MB, BAO, BCh, and an MD, and from University of Washington with an MPH. He is board certified in Internal Medicine, Pulmonary Disease and Critical Care Medicine and served on the full-time Pulmonary and Critical Care Faculty at University of Miami and Stony Brook University, where his academic research was on aerosol deposition and mucociliary clearance.
Dr. O’Riordan will begin his formal role on the Journal on March 1, 2022, taking over from founding Editor-in-Chief Gerald C. Smaldone, MD, PhD, Pulmonary, Critical Care and Sleep Division, Department of Medicine, School of Medicine, State University of New York at Stony Brook. We warmly thank Dr. Smaldone for his decades of hard work and dedication to the publication and the field. We also express our gratitude to Tim Corcoran, PhD, for his outstanding work as Associate Editor since 2014.
|
